Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Drops By 42.6%

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 360,300 shares, a decline of 42.6% from the December 31st total of 628,000 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average trading volume of 266,100 shares, the days-to-cover ratio is presently 1.4 days.

ABVC BioPharma Stock Performance

NASDAQ:ABVC opened at $0.52 on Thursday. The stock has a market capitalization of $6.76 million, a PE ratio of -0.61 and a beta of 0.70. ABVC BioPharma has a fifty-two week low of $0.41 and a fifty-two week high of $1.73. The company has a fifty day moving average of $0.54 and a two-hundred day moving average of $0.62.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.